S&P 500   3,985.08 (-2.54%)
DOW   31,950.75 (-2.16%)
QQQ   296.45 (-3.17%)
AAPL   143.69 (-3.72%)
MSFT   257.70 (-3.42%)
FB   196.78 (-2.88%)
GOOGL   2,263.40 (-2.84%)
AMZN   2,182.72 (-5.40%)
TSLA   737.29 (-3.19%)
NVDA   174.34 (-4.09%)
BABA   89.60 (-2.60%)
NIO   16.36 (-1.62%)
AMD   99.69 (-2.71%)
CGC   5.77 (-2.04%)
MU   72.36 (-2.85%)
T   20.36 (-1.02%)
GE   75.54 (-1.13%)
F   12.99 (-3.99%)
DIS   105.68 (-2.72%)
AMC   13.39 (+3.80%)
PFE   50.78 (-1.09%)
PYPL   78.41 (-1.68%)
NFLX   184.62 (-3.12%)
S&P 500   3,985.08 (-2.54%)
DOW   31,950.75 (-2.16%)
QQQ   296.45 (-3.17%)
AAPL   143.69 (-3.72%)
MSFT   257.70 (-3.42%)
FB   196.78 (-2.88%)
GOOGL   2,263.40 (-2.84%)
AMZN   2,182.72 (-5.40%)
TSLA   737.29 (-3.19%)
NVDA   174.34 (-4.09%)
BABA   89.60 (-2.60%)
NIO   16.36 (-1.62%)
AMD   99.69 (-2.71%)
CGC   5.77 (-2.04%)
MU   72.36 (-2.85%)
T   20.36 (-1.02%)
GE   75.54 (-1.13%)
F   12.99 (-3.99%)
DIS   105.68 (-2.72%)
AMC   13.39 (+3.80%)
PFE   50.78 (-1.09%)
PYPL   78.41 (-1.68%)
NFLX   184.62 (-3.12%)
S&P 500   3,985.08 (-2.54%)
DOW   31,950.75 (-2.16%)
QQQ   296.45 (-3.17%)
AAPL   143.69 (-3.72%)
MSFT   257.70 (-3.42%)
FB   196.78 (-2.88%)
GOOGL   2,263.40 (-2.84%)
AMZN   2,182.72 (-5.40%)
TSLA   737.29 (-3.19%)
NVDA   174.34 (-4.09%)
BABA   89.60 (-2.60%)
NIO   16.36 (-1.62%)
AMD   99.69 (-2.71%)
CGC   5.77 (-2.04%)
MU   72.36 (-2.85%)
T   20.36 (-1.02%)
GE   75.54 (-1.13%)
F   12.99 (-3.99%)
DIS   105.68 (-2.72%)
AMC   13.39 (+3.80%)
PFE   50.78 (-1.09%)
PYPL   78.41 (-1.68%)
NFLX   184.62 (-3.12%)
S&P 500   3,985.08 (-2.54%)
DOW   31,950.75 (-2.16%)
QQQ   296.45 (-3.17%)
AAPL   143.69 (-3.72%)
MSFT   257.70 (-3.42%)
FB   196.78 (-2.88%)
GOOGL   2,263.40 (-2.84%)
AMZN   2,182.72 (-5.40%)
TSLA   737.29 (-3.19%)
NVDA   174.34 (-4.09%)
BABA   89.60 (-2.60%)
NIO   16.36 (-1.62%)
AMD   99.69 (-2.71%)
CGC   5.77 (-2.04%)
MU   72.36 (-2.85%)
T   20.36 (-1.02%)
GE   75.54 (-1.13%)
F   12.99 (-3.99%)
DIS   105.68 (-2.72%)
AMC   13.39 (+3.80%)
PFE   50.78 (-1.09%)
PYPL   78.41 (-1.68%)
NFLX   184.62 (-3.12%)
NASDAQ:ALPN

Alpine Immune Sciences (ALPN) Stock Forecast, Price & News

$8.05
+0.05 (+0.63%)
(As of 05/18/2022 11:28 AM ET)
Add
Compare
Today's Range
$7.86
▼
$8.05
50-Day Range
$6.71
▼
$9.66
52-Week Range
$6.00
▼
$15.14
Volume
2,360 shs
Average Volume
97,349 shs
Market Capitalization
$244.16 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.74
View Price History Chart DataSkip Price History Chart
30 days | 90 days | 365 days | Advanced Chart
Receive ALPN News and Ratings via Email

Sign-up to receive the latest news and ratings for Alpine Immune Sciences and its competitors with MarketBeat's FREE daily newsletter.

Alpine Immune Sciences logo

About Alpine Immune Sciences

Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.

Headlines

May 18, 2022 | americanbankingnews.com
Alpine Immune Sciences' (ALPN) Outperform Rating Reaffirmed at Wedbush
May 16, 2022 | americanbankingnews.com
Alpine Immune Sciences (NASDAQ:ALPN) Earns "Buy" Rating from HC Wainwright
May 13, 2022 | seekingalpha.com
Alpine Immune Sciences GAAP EPS of -$0.25, revenue of $13.63M
May 13, 2022 | finance.yahoo.com
Alpine Immune Sciences, Inc. (ALPN) Reports Q1 Loss, Tops Revenue Estimates
May 12, 2022 | finance.yahoo.com
Alpine Immune Sciences Provides Corporate Update and Reports First Quarter 2022 Financial Results
May 11, 2022 | finance.yahoo.com
Alpine Immune Sciences (NASDAQ:ALPN) pulls back 14% this week, but still delivers shareholders favorable 14% CAGR over 3 years
May 10, 2022 | americanbankingnews.com
Critical Comparison: Alpine Immune Sciences (NASDAQ:ALPN) vs. Cerevel Therapeutics (NASDAQ:CERE)
April 27, 2022 | seekingalpha.com
Alpine: Rest Before Rallying Again
April 13, 2022 | finance.yahoo.com
Alpine Immune's Davoceticept Monotherapy Reduces Tumors In Early Stage Study
April 12, 2022 | finance.yahoo.com
AACR 2022: Davoceticept (ALPN-202) Monotherapy Reduces Tumors, Supports Multiple Expansion Cohorts
April 4, 2022 | finance.yahoo.com
Alpine Immune Sciences Publishes Key Preclinical Rationale for Davoceticept (ALPN-202), a First-in-Class CD28 Costimulator and Dual Checkpoint Inhibitor, in Nature Communications
March 30, 2022 | finance.yahoo.com
Alpine Immune Sciences to Host Virtual Investor Event at 2022 AACR Annual Meeting
March 24, 2022 | finance.yahoo.com
Alpine Immune Sciences, Inc. (ALPN) Soars 6%: Is Further Upside Left in the Stock?
See More Headlines

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ALPN
Previous Symbol
CUSIP
N/A
CIK
1626199
Web
www.alpineimmunesciences.com
Phone
(206) 788-4545
Fax
303-440-8399
Employees
85
Year Founded
N/A

Sales & Book Value

Annual Sales
$23.44 million
Price / Sales
10.42
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.14 per share
Price / Book
1.94

Profitability

EPS (Most Recent Fiscal Year)
($1.78)
Net Income
$-50.33 million
Net Margins
-139.41%
Pretax Margin
-139.66%
Return on Equity
-46.87%
Return on Assets
-21.39%

Debt

Debt-to-Equity Ratio
0.02
Current Ratio
2.58
Quick Ratio
2.58

Price-To-Earnings

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A

Miscellaneous

Outstanding Shares
30,330,000
Free Float
12,798,000
Market Cap
$244.16 million
Optionable
Not Optionable

Company Calendar

Last Earnings
5/12/2022
Today
5/18/2022
Next Earnings (Estimated)
8/09/2022
Fiscal Year End
12/31/2022

MarketRank™

Overall MarketRank™

2.22 out of 5 stars

Medical Sector

340th out of 1,426 stocks

Pharmaceutical Preparations Industry

137th out of 680 stocks

Analyst Opinion: 3.5Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.0 5 -4 -3 -2 -1 -













Alpine Immune Sciences (NASDAQ:ALPN) Frequently Asked Questions

Is Alpine Immune Sciences a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alpine Immune Sciences in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Alpine Immune Sciences stock.
View analyst ratings for Alpine Immune Sciences or view top-rated stocks.

When is Alpine Immune Sciences' next earnings date?

Alpine Immune Sciences is scheduled to release its next quarterly earnings announcement on Tuesday, August 9th 2022.
View our earnings forecast for Alpine Immune Sciences.

How were Alpine Immune Sciences' earnings last quarter?

Alpine Immune Sciences, Inc. (NASDAQ:ALPN) announced its quarterly earnings results on Thursday, May, 12th. The biotechnology company reported ($0.25) earnings per share for the quarter, missing analysts' consensus estimates of ($0.19) by $0.06. Alpine Immune Sciences had a negative trailing twelve-month return on equity of 46.87% and a negative net margin of 139.41%.
View Alpine Immune Sciences' earnings history.

What price target have analysts set for ALPN?

2 brokers have issued 12-month price targets for Alpine Immune Sciences' stock. Their forecasts range from $17.00 to $22.00. On average, they anticipate Alpine Immune Sciences' share price to reach $20.00 in the next twelve months. This suggests a possible upside of 148.4% from the stock's current price.
View analysts' price targets for Alpine Immune Sciences or view top-rated stocks among Wall Street analysts.

Who are Alpine Immune Sciences' key executives?
Alpine Immune Sciences' management team includes the following people:
  • Dr. Mitchell H. Gold M.D., Exec. Chairman & CEO (Age 54, Pay $817.5k)
  • Dr. Stanford Peng M.D., Ph.D., Pres and Head of R&D (Age 51, Pay $758.64k)
  • Mr. Paul Rickey, Sr. VP, CFO, Treasurer & Sec. (Age 43, Pay $551.8k)
  • Dr. Wayne R. Gombotz, Chief Technology Officer (Age 63)
  • Mr. Alexander Sharif, Director of Investor Relations & Corp. Devel.
  • Dr. Remy Durand Ph.D., Chief Bus. Officer
  • Dr. Pamela Holland Ph.D., Sr. VP of Research
What other stocks do shareholders of Alpine Immune Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alpine Immune Sciences investors own include Viking Therapeutics (VKTX), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), Abeona Therapeutics (ABEO), CymaBay Therapeutics (CBAY), Genocea Biosciences (GNCA), OPKO Health (OPK), SCYNEXIS (SCYX), Energy Transfer (ET) and Palatin Technologies (PTN).

What is Alpine Immune Sciences' stock symbol?

Alpine Immune Sciences trades on the NASDAQ under the ticker symbol "ALPN."

Who are Alpine Immune Sciences' major shareholders?

Alpine Immune Sciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Decheng Capital Management III Cayman LLC (15.53%), Frazier Life Sciences Management L.P. (13.81%), BlackRock Inc. (2.39%), Vanguard Group Inc. (2.33%), Paradigm Biocapital Advisors LP (1.11%) and State Street Corp (0.73%). Company insiders that own Alpine Immune Sciences stock include Decheng Capital China Life Sci, Life Sciences Viii L Frazier, Mitchell Gold, Orbimed Advisors Llc, Robert E Conway and Robert E Conway.
View institutional ownership trends for Alpine Immune Sciences.

Which institutional investors are selling Alpine Immune Sciences stock?

ALPN stock was sold by a variety of institutional investors in the last quarter, including Walleye Capital LLC, BlackRock Inc., Northern Trust Corp, and Bank of New York Mellon Corp.
View insider buying and selling activity for Alpine Immune Sciences or view top insider-selling stocks.

Which institutional investors are buying Alpine Immune Sciences stock?

ALPN stock was bought by a variety of institutional investors in the last quarter, including Decheng Capital Management III Cayman LLC, Frazier Life Sciences Management L.P., Paradigm Biocapital Advisors LP, Ensign Peak Advisors Inc, State Street Corp, Vanguard Group Inc., Goldman Sachs Group Inc., and Connor Clark & Lunn Investment Management Ltd.. Company insiders that have bought Alpine Immune Sciences stock in the last two years include Decheng Capital China Life Sci, Life Sciences Viii L Frazier, Orbimed Advisors Llc, and Robert E Conway.
View insider buying and selling activity for Alpine Immune Sciences or or view top insider-buying stocks.

How do I buy shares of Alpine Immune Sciences?

Shares of ALPN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Alpine Immune Sciences' stock price today?

One share of ALPN stock can currently be purchased for approximately $8.05.

How much money does Alpine Immune Sciences make?

Alpine Immune Sciences has a market capitalization of $244.16 million and generates $23.44 million in revenue each year. The biotechnology company earns $-50.33 million in net income (profit) each year or ($1.78) on an earnings per share basis.

How many employees does Alpine Immune Sciences have?

Alpine Immune Sciences employs 85 workers across the globe.

What is Alpine Immune Sciences' official website?

The official website for Alpine Immune Sciences is www.alpineimmunesciences.com.

How can I contact Alpine Immune Sciences?

Alpine Immune Sciences' mailing address is 188 East Blaine Street Suite 200, Seattle WA, 98102. The biotechnology company can be reached via phone at (206) 788-4545, via email at [email protected], or via fax at 303-440-8399.

This page was last updated on 5/18/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits Financial Juice YouTube

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.